ImmunoPrecise Antibodies Ltd. Unveils Presentation Highlighting Advances in AI-Driven Drug Discovery and Biotherapeutics

Reuters

2025/06/18

ImmunoPrecise Antibodies Ltd. Unveils Presentation Highlighting Advances in AI-Driven Drug Discovery and Biotherapeutics

ImmunoPrecise Antibodies Ltd. has presented its latest advancements and financial highlights. The company is a leading provider of biotherapeutic research and technology services, with a focus on antibody discovery and development. Notably, ImmunoPrecise has partnered with 19 of the top 20 global pharma companies and holds 25 patents. The company boasts a strong financial standing with C$12.9M in cash and no debt, maintaining a low burn rate of approximately C$1.2M per quarter. BioStrand, a part of ImmunoPrecise, has demonstrated rapid revenue growth and high gross margins, significantly contributing to the company's overall performance. The LENSai platform, acquired through BioStrand, enhances capabilities in developing new therapies and diagnostics, offering advanced data analysis and optimization of antibody sequences. The platform's HYFT technology further improves data processing efficiency, searching through extensive multi-omics databases at unprecedented speeds. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief on June 18, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544970408"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544970408\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544970408?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-18 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544970408","market":"nz","top_or_hot":-1,"title":"ImmunoPrecise Antibodies Ltd. Unveils Presentation Highlighting Advances in AI-Driven Drug Discovery and Biotherapeutics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunoPrecise Antibodies Ltd. Unveils Presentation Highlighting Advances in AI-Driven Drug Discovery and Biotherapeutics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmunoPrecise Antibodies Ltd. has presented its latest advancements and financial highlights. The company is a leading provider of biotherapeutic research and technology services, with a focus on antibody discovery and development. Notably, ImmunoPrecise has partnered with 19 of the top 20 global pharma companies and holds 25 patents. The company boasts a strong financial standing with C$12.9M in cash and no debt, maintaining a low burn rate of approximately C$1.2M per quarter. BioStrand, a part of ImmunoPrecise, has demonstrated rapid revenue growth and high gross margins, significantly contributing to the company's overall performance. The LENSai platform, acquired through BioStrand, enhances capabilities in developing new therapies and diagnostics, offering advanced data analysis and optimization of antibody sequences. The platform's HYFT technology further improves data processing efficiency, searching through extensive multi-omics databases at unprecedented speeds. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunoPrecise Antibodies Ltd. Unveils Presentation Highlighting Advances in AI-Driven Drug Discovery and Biotherapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunoPrecise Antibodies Ltd. Unveils Presentation Highlighting Advances in AI-Driven Drug Discovery and Biotherapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-18 21:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunoPrecise Antibodies Ltd. Unveils Presentation Highlighting Advances in AI-Driven Drug Discovery and Biotherapeutics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmunoPrecise Antibodies Ltd. has presented its latest advancements and financial highlights. The company is a leading provider of biotherapeutic research and technology services, with a focus on antibody discovery and development. Notably, ImmunoPrecise has partnered with 19 of the top 20 global pharma companies and holds 25 patents. The company boasts a strong financial standing with C$12.9M in cash and no debt, maintaining a low burn rate of approximately C$1.2M per quarter. BioStrand, a part of ImmunoPrecise, has demonstrated rapid revenue growth and high gross margins, significantly contributing to the company's overall performance. The LENSai platform, acquired through BioStrand, enhances capabilities in developing new therapies and diagnostics, offering advanced data analysis and optimization of antibody sequences. The platform's HYFT technology further improves data processing efficiency, searching through extensive multi-omics databases at unprecedented speeds. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDL3zq300:1","article_id":"2544970408","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544970408","pubTimestamp":1750252782,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmunoPrecise Antibodies Ltd. has presented its latest advancements and financial highlights. The company is a leading provider of biotherapeutic research and technology services, with a focus on antibody discovery and development. Notably, ImmunoPrecise has partnered with 19 of the top 20 global pharma companies and holds 25 patents. The company boasts a strong financial standing with C$12.9M in cash and no debt, maintaining a low burn rate of approximately C$1.2M per quarter. BioStrand, a part of ImmunoPrecise, has demonstrated rapid revenue growth and high gross margins, significantly contributing to the company's overall performance. The LENSai platform, acquired through BioStrand, enhances capabilities in developing new therapies and diagnostics, offering advanced data analysis and optimization of antibody sequences. The platform's HYFT technology further improves data processing efficiency, searching through extensive multi-omics databases at unprecedented speeds. You can access ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务"},"translate_title":"ImmunoPrecise Antibodies Ltd.发布演示文稿，重点介绍人工智能驱动的药物发现和生物治疗学的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPA":0.9},"content_text":"ImmunoPrecise Antibodies Ltd. Unveils Presentation Highlighting Advances in AI-Driven Drug Discovery and Biotherapeutics\n    \n\n        ImmunoPrecise Antibodies Ltd. has presented its latest advancements and financial highlights. The company is a leading provider of biotherapeutic research and technology services, with a focus on antibody discovery and development. Notably, ImmunoPrecise has partnered with 19 of the top 20 global pharma companies and holds 25 patents. The company boasts a strong financial standing with C$12.9M in cash and no debt, maintaining a low burn rate of approximately C$1.2M per quarter. BioStrand, a part of ImmunoPrecise, has demonstrated rapid revenue growth and high gross margins, significantly contributing to the company's overall performance. The LENSai platform, acquired through BioStrand, enhances capabilities in developing new therapies and diagnostics, offering advanced data analysis and optimization of antibody sequences. The platform's HYFT technology further improves data processing efficiency, searching through extensive multi-omics databases at unprecedented speeds. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief on June 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}